{
    "clinical_study": {
        "@rank": "53820", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Two dose periods in any sequence (subjects will be assigned to 1 of 2 possible sequences):\nEmixustat HCl Tablet Strength B (mid dose); 1 tablet once daily & 1 placebo tablet once daily for 7 days\nEmixustat HCl Tablet Strength A (low dose); 1 tablet twice daily for 7 days"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Three dose periods in any sequence (subjects will be assigned to 1 of 6 possible sequences):\nEmixustat HCl Tablet Strength A (low dose); 1 tablet daily for 7 days\nEmixustat HCl Tablet Strength B (mid dose); 1 tablet daily for 7 days\nEmixustat HCl Tablet Strength C (high dose); 1 tablet daily for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to characterize emixustat hydrochloride pharmacokinetic and\n      pharmacodynamic parameters in subjects with geographic atrophy associated with dry\n      age-related macular degeneration."
        }, 
        "brief_title": "Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Geographic Atrophy", 
            "Age-Related Macular Degeneration"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Atrophy", 
                "Geographic Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, randomized, masked, multiple-dose, crossover study of the\n      pharmacokinetics  of emixustat hydrochloride (HCl) in subjects with geographic atrophy (GA)\n      associated with dry age-related macular degeneration (AMD). Subjects will receive study drug\n      during multiple dose periods in a crossover design, and serve as their own controls. There\n      is a 21-28 day washout period between dose periods. The final Study Exit visit is 21 to 28\n      days after the subject's last dose of study drug at the end of the final dosing period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females age \u226565 years\n\n          -  Clinical diagnosis of GA associated with AMD\n\n          -  Able and willing to provide written informed consent\n\n          -  Able to reliably administer oral medication by self or with available assistance\n\n        Exclusion Criteria:\n\n          -  Geographic atrophy associated with a condition other than AMD\n\n          -  History of, active or high risk of developing choroidal neovascularization (CNV) in\n             either eye\n\n          -  Known serious allergy to the fluorescein sodium for injection in angiography\n\n          -  Pre-specified laboratory abnormalities at screening\n\n          -  Treatment with any investigational study drug within 30 days of screening or device\n             within 60 days of screening\n\n          -  Prior participation in any clinical study of emixustat\n\n          -  History of other disease, metabolic dysfunction, chronic immunosuppression, physical\n             examination finding\n\n          -  Male subjects who are not surgically sterile and are not willing to practice a\n             medically accepted method of birth control with their female partner of childbearing\n             potential from screening through 21 days after the last dose of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02130531", 
            "org_study_id": "4429-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "Tablet for oral administration", 
                "intervention_name": "Emixustat HCl Tablet", 
                "intervention_type": "Drug", 
                "other_name": "ACU-4429"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "Tablet for oral administration", 
                "intervention_name": "Placebo Tablet", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98101"
                }, 
                "name": "Call Acucela Clinical Trials Helpdesk for locations"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration", 
        "overall_contact": {
            "email": "clinicaltrials@acucela.com", 
            "last_name": "Acucela Clinical Trials Helpdesk", 
            "phone": "206-805-8310"
        }, 
        "overall_official": {
            "affiliation": "Acucela Inc.", 
            "last_name": "Acucela Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Concentration-Time Curve from time zero to 24 hours [(AUC(0-24h)]", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7 of each dosing period"
            }, 
            {
                "measure": "Degree of suppression of the ERG b-wave response post-photobleaching.", 
                "safety_issue": "No", 
                "time_frame": "Screening through Day 10 of each dosing period and study exit"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02130531"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Acucela Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acucela Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}